Search Results - "Padulles, Nuria"

Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology by Alsoud, Dahham, Moes, Dirk Jan A R, Wang, Zhigang, Soenen, Rani, Layegh, Zohra, Barclay, Murray, Mizuno, Tomoyuki, Minichmayr, Iris K, Keizer, Ron J, Wicha, Sebastian G, Wolbink, Gertjan, Lambert, Jo, Vermeire, Séverine, de Vries, Annick, Papamichael, Konstantinos, Padullés-Zamora, Núria, Dreesen, Erwin

“…Infliximab, an anti-tumor necrosis factor monoclonal antibody, has revolutionized the pharmacological management of immune-mediated inflammatory diseases…”
Get full text

Contribution of infliximab population pharmacokinetic model for dose optimization in ulcerative colitis patients by Santacana Juncosa, Eugènia, Padullés Zamora, Ariadna, Colom Codina, Helena, Rodríguez Alonso, Lorena, Guardiola Capo, Jordi, Bas Minguet, Jordi, Padullés Zamora, Núria

Get full text

Disease-modifying treatments for patients with multiple sclerosis in Spain by Pérez, Alejandro Santiago, Casado, Santos Esteban, Álvarez Payero, Miriam, Escolano Pueyo, Ángel Escolano, Arévalo Bernabé, Ángel Guillermo, Padullés Zamora, Núria, Diaz Ruiz, Pilar, López González, Ana María

“…Multiple sclerosis is a chronic demyelinating disease of the central nervous system and long-term disabling. Different disease-modifying treatments are…”
Get more information

Bayes‐based dosing of infliximab in inflammatory bowel diseases: Short‐term efficacy by Santacana Juncosa, Eugènia, Rodríguez‐Alonso, Lorena, Padullés Zamora, Ariadna, Guardiola, Jordi, Rodríguez‐Moranta, Francisco, Serra Nilsson, Katja, Bas Minguet, Jordi, Morandeira Rego, Francisco, Colom Codina, Helena, Padullés Zamora, Núria

“…Aims Therapeutic drug monitoring of infliximab can guide clinical decisions in patients with loss of response and in those who can benefit from a…”
Get full text

Relationship between vedolizumab serum concentrations in the induction phase and early and sustained response in the first year of treatment in patients with ulcerative colitis by Sánchez-Hernández, José Germán, Rebollo, Noemí, Muñoz, Fernando, Padullés-Zamora, Nuria, Miarons, Marta, Martín Gutiérrez, Nerea, Martín Gil, Marcos, Otero, María José

“…Evidence on the usefulness of proactive monitoring of vedolizumab serum concentrations during the induction phase of treatment is limited. The objective of our…”
Get more information

Is there a difficulty in maintaining haemoglobin target levels in pre-dialysis patients treated with erythropoiesis-stimulating agents? by Santacana-Juncosa, Eugènia, Padullés-Zamora, Núria, Padullés-Zamora, Ariadna, Comas-Sugrañes, Dolors, Santulario-Verdú, Lorena, Sanmartí-Martínez, Núria, Martínez-Castelao, Alberto

Get more information

Predictors of Infliximab Trough Concentrations in Inflammatory Bowel Disease Patients Using a Repeated-Measures Design by Santacana, Eugènia, Rodríguez-Alonso, Lorena, Padullés, Ariadna, Guardiola, Jordi, Bas, Jordi, Rodríguez-Moranta, Francisco, Serra, Katja, Morandeira, Francisco, Colom, Helena, Padullés, Núria

“…Treating patients based on a treat-to-trough approach has been shown to be a cost-effective strategy for inflammatory bowel disease (IBD) patients who have…”
Get full text

Methylprednisolone Pulses Plus Tacrolimus in Addition to Standard of Care vs. Standard of Care Alone in Patients With Severe COVID-19. A Randomized Controlled Trial by Solanich, Xavier, Antolí, Arnau, Rocamora-Blanch, Gemma, Padullés, Núria, Fanlo-Maresma, Marta, Iriarte, Adriana, Mitjavila, Francesca, Capdevila, Olga, Riera-Mestre, Antoni, Bas, Jordi, Vicens-Zygmunt, Vanesa, Niubó, Jordi, Calvo, Nahum, Bolivar, Santiago, Rigo-Bonnin, Raúl, Mensa-Vilaró, Anna, Arregui, Laura, Tebe, Cristian, Videla, Sebastià, Hereu, Pilar, Corbella, Xavier

“…Introduction: Severe lung injury is triggered by both the SARS-CoV-2 infection and the subsequent host-immune response in some COVID-19 patients. Methods: We…”
Get full text

Intravenous Human Plasma-Derived Augmentation Therapy in α1-Antitrypsin Deficiency: From Pharmacokinetic Analysis to Individualizing Therapy by Zamora, Nuria Padullés, Pla, Rafael Vidal, Rio, Pilar Gispert Del, Margaleff, Rosendo Jardi, Frias, Francisco Rodriguez, Ronsano, Jose Bruono Montero

“…Background: Severs forms of α1-antitrypsin (AAT) deficiency require augmentation therapy by intravenous administration of purified preparations of AAT…”
Get full text

External Evaluation of Population Pharmacokinetic Models of Infliximab in Patients With Inflammatory Bowel Disease by Santacana, Eugènia, Rodríguez-Alonso, Lorena, Padullés, Ariadna, Guardiola, Jordi, Rodríguez-Moranta, Francisco, Serra, Katja, Bas, Jordi, Morandeira Biology, Francisco, Colom, Helena, Padullés, Núria

“…Infliximab (IFX) trough levels vary markedly between patients with inflammatory bowel disease (IBD), which is important for clinical response. The aim of this…”
Get full text

SAT-009-Pharmacokinetics of ertapenem in plasma and ascitic fluid in cirrhotic patients with spontaneous bacterial peritonitis by Amador, Alberto, Cobo, Sara, Padulles, Ariadna, Rigo, Raul, Grau, Inmaculada, Tubau, Fe, Garcia-Sumalla, Albert, Zamora, Nuria Padullés, Castellote, José

Get full text

HLA-B57: 01 genotyping in the prevention of hypersensitivity to abacavir: 5 years of experience by Ruiz-Iruela, Cristina, Padullés-Zamora, Núria, Podzamczer-Palter, Daniel, Alonso-Pastor, Arnald, Candás-Estébanez, Beatriz, Alía-Ramos, Pedro, Padró-Miquel, Ariadna

“…INTRODUCTIONMost of the cost-effectiveness analyses are based on estimations to make decisions on the future implementation of a test. However, the model…”
Get full text

Intravenous Human Plasma-Derived Augmentation Therapy in {alpha}1-Antitrypsin Deficiency: From Pharmacokinetic Analysis to Individualizing Therapy by Zamora, Nuria Padulles, Pla, Rafael Vidal, Del Rio, Pilar Gispert, Margaleff, Rosendo Jardi, Frias, Francisco Rodriguez, Ronsano, Jose Bruono Montoro

Get full text

Social pharmacology of the information about prescription drugs on the Internet by Juárez-Giménez, Juan Carlos, Padullés-Zamora, Nuria, Lalueza-Broto, Pilar, Girona-Brumos, Lourdes

Get more information

[Translated Article] Disease-modifying treatments for patients with multiple sclerosis in Spain by Pérez, Alejandro Santiago, Casado, Santos Esteban, Payero, Miriam Álvarez, Pueyo, Ángel Escolano, Bernabé, Ángel Guillermo Arévalo, Zamora, Núria Padullés, Ruiz, Pilar Diaz, González, Ana María López

“…Multiple sclerosis is a chronic demyelinating disease of the central nervous system and long-term disabling. Different disease-modifying treatments are…”
Get full text

Intravenous human plasma-derived augmentation therapy in alpha 1-antitrypsin deficiency: from pharmacokinetic analysis to individualizing therapy by Zamora, Nuria Padullés, Pla, Rafael Vidal, Del Rio, Pilar Gispert, Margaleff, Rosendo Jardi, Frias, Francisco Rodriguez, Ronsano, Jose Bruno Montoro, Ronsano, Jose Bruono Montoro

“…Severe forms of alpha(1)-antitrypsin (AAT) deficiency require augmentation therapy by intravenous administration of purified preparations of AAT concentrate…”
Get full text

Use of methoxy polyethylene glycol-epoetin beta in stage 3, 4 or 5 non-dialysis chronic kidney disease by Padullés-Zamora, Núria, Comas-Sugrañes, Dolors, Pineda-Yuste, M del Mar, Jódar-Masanés, Ramon, Martínez-Castelao, Alberto

“…Methoxy polyethylene glycol-epoetin beta (PEG-EPO) is indicated for the treatment of anaemia due to chronic kidney disease. Its long half-life allows it to be…”
Get more information

Pharmacokinetics of α1-Antitrypsin Replacement Therapy in Severe Congenital Emphysema by Pla, Rafael Vidal, Zamora, Nuria Padullés, Piñol, Ferran Sala, Margaleff, Rosendo Jardi, Frias, Francisco Rodríguez, Montoro Ronsano, José Bruno

Get full text

Pharmacokinetics of α 1-Antitrypsin Replacement Therapy in Severe Congenital Emphysema by Pla, Rafael Vidal, Zamora, Nuria Padullés, Piñol, Ferran Sala, Margaleff, Rosendo Jardi, Frias, Francisco Rodríguez, Montoro Ronsano, José Bruno

“…α 1-antitrypsin (AAT) deficiency is a codominant autosomal genetic disorder that predisposes a patient to chronic obstructive pulmonary disease and emphysema…”
Get full text

[Translated Article] Disease-modifying treatments for patients with multiple sclerosis in Spain by Pérez, Alejandro Santiago, Casado, Santos Esteban, Payero, Miriam Álvarez, Pueyo, Ángel Escolano, Bernabé, Ángel Guillermo Arévalo, Zamora, Núria Padullés, Ruiz, Pilar Diaz, González, Ana María López

“…Multiple sclerosis is a chronic demyelinating disease of the central nervous system and long-term disabling. Different disease-modifying treatments are…”
Get more information